Pacira Biosciences Stock Performance
| PCRX Stock | USD 21.00 0.64 3.14% |
The company holds a Beta of 0.85, which implies possible diversification benefits within a given portfolio. Pacira BioSciences returns are very sensitive to returns on the market. As the market goes up or down, Pacira BioSciences is expected to follow. At this point, Pacira BioSciences has a negative expected return of -0.11%. Please make sure to check Pacira BioSciences' mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and daily balance of power , to decide if Pacira BioSciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pacira BioSciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 3.14 | Five Day Return 2.29 | Year To Date Return (14.15) | Ten Year Return (63.93) | All Time Return 199.15 |
1 | Disposition of 12060 shares by Shawn Cross of Pacira BioSciences, at 22.09 subject to Rule 16b-3 | 11/10/2025 |
2 | Why Pacira BioSciences Is Up 7.8 percent After Activist Urges Full Sale Process | 11/17/2025 |
3 | Acquisition by Kronenfeld Mark A. of 5230 shares of Pacira BioSciences, subject to Rule 16b-3 | 11/21/2025 |
4 | Pacira BioSciences Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance | 12/10/2025 |
5 | Acquisition by Brendan Teehan of 402 shares of Pacira BioSciences at 10.763 subject to Rule 16b-3 | 12/31/2025 |
6 | Disposition of 9272 shares by Frank Lee of Pacira BioSciences at 24.46 subject to Rule 16b-3 | 01/02/2026 |
7 | Disposition of 1416 shares by Lauren Riker of Pacira BioSciences at 24.24 subject to Rule 16b-3 | 01/05/2026 |
8 | Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues | 01/08/2026 |
9 | Pacira BioSciences Shares Down 6.9 percent - Whats Next - MarketBeat | 01/15/2026 |
10 | Insider Trading | 01/27/2026 |
11 | Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors | 01/28/2026 |
12 | Disposition of 41488 shares by Frank Lee of Pacira BioSciences at 20.54 subject to Rule 16b-3 | 01/30/2026 |
13 | Disposition of 13137 shares by Williams Kristen of Pacira BioSciences at 20.53 subject to Rule 16b-3 | 02/02/2026 |
14 | Avoiding Lag Real-Time Signals in Movement - Stock Traders Daily | 02/04/2026 |
| Begin Period Cash Flow | 153.3 M | |
| Total Cashflows From Investing Activities | -83.3 M |
Pacira BioSciences Relative Risk vs. Return Landscape
If you would invest 2,307 in Pacira BioSciences on November 9, 2025 and sell it today you would lose (207.00) from holding Pacira BioSciences or give up 8.97% of portfolio value over 90 days. Pacira BioSciences is currently does not generate positive expected returns and assumes 2.8817% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Pacira, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pacira BioSciences Target Price Odds to finish over Current Price
The tendency of Pacira Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 21.00 | 90 days | 21.00 | about 86.56 |
Based on a normal probability distribution, the odds of Pacira BioSciences to move above the current price in 90 days from now is about 86.56 (This Pacira BioSciences probability density function shows the probability of Pacira Stock to fall within a particular range of prices over 90 days) .
Pacira BioSciences Price Density |
| Price |
Predictive Modules for Pacira BioSciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pacira BioSciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Pacira BioSciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pacira BioSciences is not an exception. The market had few large corrections towards the Pacira BioSciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pacira BioSciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pacira BioSciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.12 | |
β | Beta against Dow Jones | 0.85 | |
σ | Overall volatility | 2.17 | |
Ir | Information ratio | -0.04 |
Pacira BioSciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pacira BioSciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pacira BioSciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pacira BioSciences generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 700.97 M. Net Loss for the year was (99.56 M) with profit before overhead, payroll, taxes, and interest of 470.65 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Avoiding Lag Real-Time Signals in Movement - Stock Traders Daily |
Pacira BioSciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pacira Stock often depends not only on the future outlook of the current and potential Pacira BioSciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pacira BioSciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 46.2 M | |
| Cash And Short Term Investments | 484.6 M |
Pacira BioSciences Fundamentals Growth
Pacira Stock prices reflect investors' perceptions of the future prospects and financial health of Pacira BioSciences, and Pacira BioSciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pacira Stock performance.
| Return On Equity | 0.029 | ||||
| Return On Asset | 0.0289 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 41.1 M | ||||
| Price To Earning | 14.34 X | ||||
| Price To Book | 1.15 X | ||||
| Price To Sales | 1.26 X | ||||
| Revenue | 700.97 M | ||||
| Gross Profit | 470.65 M | ||||
| EBITDA | 29.12 M | ||||
| Net Income | (99.56 M) | ||||
| Cash And Equivalents | 316.39 M | ||||
| Cash Per Share | 6.90 X | ||||
| Total Debt | 638.85 M | ||||
| Debt To Equity | 1.10 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 16.93 X | ||||
| Cash Flow From Operations | 189.39 M | ||||
| Earnings Per Share | 0.47 X | ||||
| Market Capitalization | 903.45 M | ||||
| Total Asset | 1.55 B | ||||
| Retained Earnings | (206.36 M) | ||||
| Working Capital | 435.21 M | ||||
| Current Asset | 252.58 M | ||||
| Current Liabilities | 149.79 M | ||||
About Pacira BioSciences Performance
Evaluating Pacira BioSciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Pacira BioSciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pacira BioSciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 241.48 | 124.60 | |
| Return On Tangible Assets | (0.08) | (0.08) | |
| Return On Capital Employed | (0.05) | (0.06) | |
| Return On Assets | (0.06) | (0.06) | |
| Return On Equity | (0.13) | (0.12) |
Things to note about Pacira BioSciences performance evaluation
Checking the ongoing alerts about Pacira BioSciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pacira BioSciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pacira BioSciences generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 700.97 M. Net Loss for the year was (99.56 M) with profit before overhead, payroll, taxes, and interest of 470.65 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Avoiding Lag Real-Time Signals in Movement - Stock Traders Daily |
- Analyzing Pacira BioSciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pacira BioSciences' stock is overvalued or undervalued compared to its peers.
- Examining Pacira BioSciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pacira BioSciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pacira BioSciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pacira BioSciences' stock. These opinions can provide insight into Pacira BioSciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences' price analysis, check to measure Pacira BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences is operating at the current time. Most of Pacira BioSciences' value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences' price. Additionally, you may evaluate how the addition of Pacira BioSciences to your portfolios can decrease your overall portfolio volatility.